Kawano Takahisa, Saito Takako, Yasu Takanori, Saito Tomoyuki, Nakamura Tomohiro, Namai Kazuyuki, Tamemoto Hiroyuki, Kawakami Masanobu, Saito Muneyasu, Ishikawa San-e
Department of Medicine, Omiya Medical Center, Jishi Medical School, Saitama 330-8503, Japan.
Metabolism. 2005 May;54(5):653-6. doi: 10.1016/j.metabol.2004.12.009.
Adiponectin is an adipose-derived cytokine, and it is suggested that hypoadiponectinemia increases the prevalence of ischemic heart disease (IHD). The present study was undertaken to determine serum adiponectin levels in patients with arteriosclerosis obliterans (ASO) and IHD. Forty-nine patients with ASO and 49 age-, sex-, and body mass index-matched control subjects were examined. The diagnosis of ASO was derived from an ankle brachial index of less than 0.90 and stenotic or obstructive change in angiogram. Ischemic heart disease was diagnosed by ischemic or stenotic change in ECG, treadmill, or coronary angiogram. Serum adiponectin level was 8.6 +/- 0.9 microg/mL in the patients with ASO, a value significantly less than that of 12.4 +/- 1.0 microg/mL in the control subjects ( P < .01). Next, we subgrouped the subjects into 4 groups according to the presence of ASO and IHD. Serum adiponectin levels were 9.4 +/- 1.5 and 10.2 +/- 1.6 microg/mL in the subjects with ASO (n =23) and those with IHD (n = 13), respectively. It was further reduced to 7.9 +/- 1.2 microg/mL in the subjects having both ASO and IHD (n = 26), a value significantly less than that of 13.2 +/- 1.4 microg/mL in the control subjects (n = 36; P < .05). Serum high-density lipoprotein cholesterol was significantly less in the subjects with ASO than in the control subjects (42.1 +/- 1.7 vs 48.5 +/- 2.0 mg/dL; P < .05), but there were no differences in blood pressure, total cholesterol, low-density lipoprotein cholesterol, triglyceride, and uric acid levels. The present results indicate that a reduction in serum adiponectin level is associated with the prevalence and magnitude of systemic atherosclerosis including IHD and ASO.
脂联素是一种脂肪源性细胞因子,有研究表明低脂联素血症会增加缺血性心脏病(IHD)的患病率。本研究旨在测定闭塞性动脉硬化症(ASO)和IHD患者的血清脂联素水平。对49例ASO患者和49例年龄、性别及体重指数相匹配的对照者进行了检查。ASO的诊断依据为踝臂指数小于0.90以及血管造影显示有狭窄或阻塞性改变。缺血性心脏病通过心电图、跑步机运动试验或冠状动脉造影显示的缺血或狭窄改变来诊断。ASO患者的血清脂联素水平为8.6±0.9μg/mL,显著低于对照者的12.4±1.0μg/mL(P<0.01)。接下来,我们根据是否存在ASO和IHD将受试者分为4组。ASO患者(n = 23)和IHD患者(n = 13)的血清脂联素水平分别为9.4±1.5和10.2±1.6μg/mL。同时患有ASO和IHD的受试者(n = 26)的血清脂联素水平进一步降至7.9±1.2μg/mL,显著低于对照者(n = 36)的13.2±1.4μg/mL(P<0.05)。ASO患者的血清高密度脂蛋白胆固醇显著低于对照者(42.1±1.7 vs 48.5±2.0mg/dL;P<0.05),但血压、总胆固醇、低密度脂蛋白胆固醇、甘油三酯和尿酸水平无差异。目前的结果表明,血清脂联素水平降低与包括IHD和ASO在内的全身性动脉粥样硬化的患病率及严重程度相关。